Abstract:Objective: This study aimed to evaluate the efficacy of α-thalassemia gene testing as a part of an antenatal intervention program over a 10-year period. Methods: All patients underwent α-thalassemia gene testing, which included the analysis of three types of deletions and mutations. Rare α-thalassemia gene testing was performed using Sanger sequencing, multiplex ligation-dependent probe amplification, and sequencing techniques. Prenatal diagnosis was performed in high-risk couples using chorionic villus sampling or amniocentesis. Results: From 2010 to 2019, among the 91,852 patients examined, α-thalassemia mutations were identified in 41.78% of patients. The most frequent α 0 gene mutation was-- SEA , followed by-- THAI . Two rare α 0 -thalassemia gene mutations at -- 32.8 and -- 230 , were also observed. A total of 2,235 high-risk couples were identified, of which 562 were affected, including three with the-- SEA /-- THAI genotype and one with the-- SEA /-- 230 genotype. Additionally, prenatal diagnosis revealed four cases of fetal anemia and/or mild edema, along with two cases of severe fetal edema. Chromosome and gene chip results were normal. Thalassemia gene testing showed an α CS α/α CS α genotype in four patients with anemia and/or mild edema, while two patients with severe fetal edema had one-- SEA /α CS α genotype and one-- SEA /-- GX genotype. Using the cut-off points of 74.6 fL and 24.4 pg as criteria for identifying α 0 -thalassemia carriers and HbH disease, the detection rate of missed diagnoses in high-risk couples is consistent with national guidelines for standards, potentially saving 10,217,700 ¥. Conclusion: Routine molecular testing for α-thalassemia in high-risk prenatal populations effectively prevented severe α-thalassemia births. Despite the high cost, the cutoff points proposed by this study suggest that implementing screening using a new parameter has the potential to reduce current expenses.

Detection of alpha-thalassemia in China by using multiplex ligation-dependent probe amplification

Prevention of Hb Bart’s (γ4) Disease Associated with the – –Thaiα0-Thalassemia Deletion in Mainland China

AB034. Hemoglobinopathies in China and SEA: Rapid Targeted Deep Sequencing for Molecular Screening and Clinical Genotyping in Subjects with Hemoglobinopathies

Development and clinical validation of a novel detection kit for α-thalassemia in southern Chinese

[Rapid Detection of Non-Deletional Alpha-Thalassemia Mutations by PCR-LIS-SSCP].

Development of a Quantitative Multiplex PCR to Detect Three Common Alpha Thalassemia Deletions

Combination of Multiplex Ligation-Dependent Probe Amplification with Gene Sequencing Technology for Detecting Gene Defect of Thalassemia

A Simple, Rapid, and Highly Sensitive Electrochemical DNA Sensor for the Detection of α- and β-Thalassemia in China

Analysis of the drawback of the combination of MLPA and gene sequencing technology in detecting thalassemia genes

Detection of the Point Mutations of α-Thalassemia by Reverse Dot Blot

Detection of rare thalassemia mutations using long-read single-molecule real-time sequencing

Analysis of deletional hereditary persistence of fetal hemoglobin/δβ-thalassemia and δ-globin gene mutations in Southerwestern China

A Nested Asymmetric PCR Melting Curve Assay for One-Step Genotyping of Nondeletional α-Thalassemia Mutations

Accurate detection of α-globin gene copy number variants with two reactions using droplet digital PCR

Molecular spectrum and prevalence of thalassemia investigated by third-generation sequencing in the Dongguan region of Guangdong Province, Southern China

Mutation spectrum of thalassemia among pre-pregnant adults in the Jiangsu Province by capillary electrophoresis-based multiplex PCR assay

Prenatal diagnosis of beta-thalassemia by reverse dot-blot hybridization in southern China

Study on Prenatal Screening and Genotype Analysis of Α-Thalassemia

Invasive Molecular Prenatal Diagnosis of Alpha and Beta Thalassemia among Hakka Pregnant Women

Application of real‐time PCR–based multicolor melting curve with automatic analysis system in pregestational and prenatal thalassemia diagnoses

Routine antenatal molecular testing for α-thalassemia at a tertiary referral hospital in China: ten years of experience